For the past year, the world has been under the grip of the intensely contracting Coronavirus, the deadly pandemic which spread its wings from the food market in Wuhan, China. The highly contracting virus has spread to all the prime countries in the world including the United States of America, Brazil and the United Kingdom.
The spread of the virus has led to the aforementioned countries being called the epicentres of the virus spreading activity with diplomatic tensions rising, economic sanctions being imposed and trade relations between countries changing as the entire dynamics of the world business environment has changed completely. With incessant lockdowns and weakening of the medical infrastructure of the country, the faults and cracks in the system have been considerably exposed.
India being the epicentre of the virus has entrusted a lot of responsibility on the Serum Institute of India in Pune led by Adar Poonawalla. Serum Institute is the biggest producer of the vaccine vials in the country and has been given the responsibility of developing the vaccine and distributing among the population. The Indian Government has taken the responsibility of accessing the Oxford Astrazeneca Vaccine which is currently in its second and third medical trails. Currently, the vaccine is being implemented on more than 20000 samples and the results are being analysed systematically.
However, the Indian Government has ratified the selling and distribution of the vaccine among the rural and urban population of the country. The Pfizer NBiotech Vaccine that is being developed in the United States of America and which has more than 90% efficiency rate has also been granted a disbursal certificate by the Indian Council of Medical Research and the Serum Institute of India. The vaccine is currently under its third stage of clinical trial and will be available in the market within a timeframe of a few months.
The Oxford Vaccine which has been given the name Covishield has more than 60% Vaccine Efficiency and is also currently under the third stage of a clinical trial. Covishield was well tolerated with reference to solicited adverse events and wasn't related to an increased number of SAEs and deaths. A majority of solicited reactions were mild in severity and resolved with none sequelae. Therefore, Covishield is safe and well-tolerated and may be used effectively for prevention of COVID-19 within the targeted population.
The vaccine has been granted to be used in countries like the USA and Brazil, both of whom have been granted the recommendation and proposal to distribute the vaccine among the population.
The biggest advantage of the Covishield Vaccine is that it can be stored in a temperature range of 2°Celsius to 8°Celsius. Previously it was being argued that the vaccine needs to be stored in room temperatures which ranged from -40°Celsius to -80°Celsius. But further studies have concluded the fact that the vaccine can be stored in relatively low temperatures and can easily be distributed among both the urban and the rural population.
There have been grants of acceptance by the Drug Authorities of India like the Drug Controller General of India and the other eminent medical establishments in the country. Some of the chiefs of these medical establishments have stated that the Government is looking to become Atma nirbhar (which means that the country is looking to become self-dependent) and has also advocated the policy of vocal locality. This was the reason why the Serum Institute of India possessing a huge capacity had started creating storage facilities for the vaccine in different parts of the country.
The inoculation program of the vaccine has also been segregated by the Government of India. Statistical records and analysis of the frontline workers who are responsible for delegating duties in Covid Department have been taken. Thus, it is first being prioritized that the frontline workers would be receiving the first dosage of the vaccine. Secondly, the second batch of the vaccine would be distributed among the people with comorbid conditions and ailments in their body.
The government is looking to regulate the vaccine quickly into the market and is looking to distribute the vaccine as soon as possible in the market.
Thus Serum Institute of India in Pune will be at the forefront of the Vaccine Development Drive that is taking place in India to eradicate the menace of Coronavirus from the country. Although the fact that whether the virus would diminish or not is debatable the country is expecting for a sea change in the fortunes after the inoculation drive of the vaccine in the market.